Loading the company…
Loading the company…
㈜에이탑메드
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-09 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 2020. Industry: Wholesale & Retail. Revenue for 2025 was ₩26.2bn. It has 26 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2022-08-30 · latest registration 2025-03-28 · newest first
본 발명은 항균제 조성물, 이의 제조방법 및 이를 이용한 원단에 관한 것으로, 상기 항균제 조성물은 구리 이온과 약재 추출물을 포함하여 약재 추출물에 의해 구리 이온이 환원되는 형태로 중금속 독성을 감소시키고, 중성 유황수와 구연산을 포함하여 섬유에 킬레이트화 흡착을 형성하여 내구성이 향상되는 이점이 있다.
본 발명에 따른 의료용 압박밴드는 원사들이 경편 조직 및 위편 조직 중에서 선택된 하나의 조직으로 제편된 편물 구조를 구비하며, 상기 원사들은 심사가 1차 효과사와 2차 효과사에 의해 차례로 2회 커버링되어 있는 더블 커버링 원사이고, 상기 심사는 스판덱스 원사이고, 상기 2차 효과사는 폴리에스터 폴리머인 코어부와 친수성기를 갖는 흡수성 폴리머인 쉬스부가 복합방사되어 있는 코어-쉬스형(Core-sheath type) 복합섬유를 포함하는 것을 특징으로 한다. 본 발명에 따른 의료용 압박밴드는 인체에서 배출되는 수분 및 땀을 빨리 흡수 후 확신시킬 수 있어서 우수한 열전도성과 접촉 냉감성을 발현함과 동시에 통기성과 착용감을 향상시켜 준다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 23.2 | 26.2 |
| Cost of sales | 20.7 | 23.4 |
| Gross profit (loss) | 2.5 | 2.7 |
| Selling, general and administrative expenses | 1.9 | 2.0 |
| Operating income (loss) | 0.6 | 0.7 |
| Non-operating income | 0.0 | 0.0 |
| Other gains | 0.0 | 0.0 |
| Finance income | 0.0 | 0.0 |
| Non-operating expenses | 0.4 | 0.4 |
| Other losses | 0.0 | 0.0 |
| Finance costs | 0.4 | 0.3 |
| Profit (loss) before tax | 0.2 | 0.4 |
| Income tax expense | 0.0 | 0.1 |
| Net income (loss) | 0.2 | 0.3 |
Revenue ₩26.2bn, up 12.9% YoY.
Operating margin 2.7% (prior 2.7%).
Net income ₩0.3bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06